European Society of Cardiology Congress 2014
ODYSSEY long term
Low density lipoprotein cholesterol (LDL-C) was reduced by 60% in patients treated an investigational PCSK9 inhibitor, Alirocumab in addition to statin therapy, for about 52 weeks in the ODYSSEY study. The lead investigator, Professor Jennifer Robinson discusses how this was translated into a reduction in…
read more »
ODYSSEY FH and patient unmet needs
Less than 1% of people with familial hypercholesterolaemia (FH), the commonest genetic disorder in the world are diagnosed. As FH patients have significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) their consequent risk of cardiovascular death is greatly increased. Therefore, the results of the ODYSSEY…
read more »
ODYSSEY FHI FHII
Fewer than 80% of familial hypercholesterolaemia (FH) patients achieved an LDL-C level of
read more »
Are PCSK9 levels predictive of future CVD?
A study from the Karolinska Institutet (Stockholm, Sweden) points to further evaluation of this question. The association between serum PCSK9 levels and risk for first cardiovascular events was studied in a cohort study of 4,232 men and women (60 years at recruitment), in Stockholm, Sweden….
read more »
ODYSSEY trials at ESC Congress Hotline
ESC Congress 2014: Lipids Hotline: ODYSSEY TRIALS Prof Alberto Zambon, University of Padua, Italy discusses the four ODYSSEY trials with the PCSK9 inhibitor alirocumab presented at ESC Congress Hotline Sunday. Addition of a new investigational agent – Alirocumab – to high doses of statins result…
read more »
FH is a family disorder
For every one patient there are an additional 8 cases of familial hypercholesterolaemia (FH) to be diagnosed – Katherine Wilemon, Founder, President and CEO of the FH Foundation: see http://thefhfoundation.org/ Underdiagnosis and undertreatment of FH are major issues. The clinical relevance is underlined by evidence…
read more »
ESC Congress 2014: ODYSSEY trials shine at Hotline 2
PCSK9 continued to create buzz at ESC Congress 2014, with impressive results from four trials from the ODYSSEY Phase III Programme with alirocumab. All four trials address patient populations with unmet clinical needs. Two of the trials were in patients with familial hypercholesterolaemia (FH), now…
read more »
PCSK9 inhibition: continues to show promise for unmet clinical needs
Today at ESC Congress 2014 PCSK9 inhibition: continues to show promise for unmet clinical needs Debate has raged following the launch of guidelines in the US and UK (NICE) which have done away with targets and instead focused on cardiovascular (CV) risk. Yet…
read more »
